Pegfilgrastim (Fulphila; Neulasta; Neulasta Onpro; Nyvepria; Udenyca; Ziextenzo) J2506

Pegfilgrastim is covered for prophylaxis of febrile neutropenia in patients with nonmyeloid malignancies receiving myelosuppressive chemotherapy that carries a clinically significant risk of febrile neutropenia, and should be administered per the FDA-approved schedule (starting ≥24 hours after chemotherapy). Routine same-day (same-day as chemotherapy) administration is not recommended, but may be considered as an exception when clear documentation shows significant patient/caregiver barriers to returning for next-day dosing.

"Pegfilgrastim is covered for prophylaxis to decrease the incidence of infection (manifested by febrile neutropenia) in patients with nonmyeloid malignancies receiving myelosuppressive cancer chemot..."

Sign up to see full coverage criteria, indications, and limitations.